Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed to boost immune responses to vaccines and will be utilized by Pfizer for up to two infectious diseases. While Pfizer will oversee the development, manufacturing, and commercialization of the resulting products, Novavax remains responsible for the delivery and supply of the Matrix-M adjuvant itself.

Earlier on January 10, Pfizer Inc. (NYSE: PFE) announced positive results from Cohort 3 of its pivotal BREAKWATER trial. This specific randomized cohort evaluated the BRAFTOVI regimen in combination with cetuximab and FOLFIRI for patients with previously untreated metastatic colorectal cancer harboring a BRAF V600E mutation.

The study showed that adding the chemotherapy backbone to the BRAFTOVI regimen significantly increased response rates. The analysis showed an objective response rate of 64% for the BRAFTOVI combination, compared to 39% for the standard-of-care treatment (FOLFIRI with or without bevacizumab). Pfizer noted these statistically significant results highlight potential flexibility in chemotherapy options for this patient population.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.